CLINICAL RESEARCH PROTOCOLS FOR GENITOURINARY CANCERS

Testicular Cancer

Phase III

FRE-FNCLCC-T93BP, EU-96016, FRE-T93BP Phase III Randomized Study of Etoposide/Cisplatin vs Bleomycin/Etoposide/Cisplatin (BEP) in Good-Prognosis Advanced Germ Cell Cancer


FRE-IT94, NCI-F94-0019, FRE-FNCLCC-IT94 Phase III Randomized Study of Salvage Therapy With PEI (CDDP/VP-16/IF) or VeIP (VBL/IFF/CDDP) Alone or Followed by High-Dose CarboPEC (CBDCA/VP-16/CTX) and ABMT/PBSC Rescue for Germ Cell Tumors in Relapse or First Partial Remission


EORTC-30983 Phase III Randomized Study of Bleomycin/Cisplatin/Etoposide (BEP) Versus Bleomycin/Cisplatin/Etoposide/Paclitaxel (T-BEP) in Men With Intermediate Prognosis Germ Cell Cancer


EORTC-30974 Phase III Randomized Study of Standard Cisplatin, Etoposide, and Ifosfamide (VIP) Followed By Sequential High Dose VIP and Stem Cell Rescue Versus Bleomycin, Etoposide, and Cisplatin (BEP) in Chemotherapy-Naive Men With Poor Prognosis Germ Cell Cancer


MRC-TE19, EU-97003, EORTC-30982 Phase III Randomized Study of Adjuvant Radiotherapy versus a Single Cycle of Carboplatin in the Treatment of Stage I Testicular Seminoma


MSKCC-94076, NCI-T94-0086D, E-3894 Phase III Randomized Study of BEP (BLEO/VP-16/CDDP) Alone vs BEP Followed by High-Dose CBDCA/VP-16/CTX With Hematopoietic Rescue in Males With Previously Untreated Poor and Intermediate Risk Germ Cell Tumors

Chairperson: Robert J. Motzer. Telephone: 212-639-6667. Lead organization: Memorial Sloan-Ket-
Renal Cell Cancer

**Phase III**

**NCI-91-C-0094B, NCI-T91-0053N** Phase III Randomized Study of Intravenous Low-Dose vs Intravenous High-Dose vs Subcutaneous IL-2 for Metastatic Renal Cell Carcinoma


**CWG-LU-8520, NCI-V97-1351** Phase III Randomized Study of Adjuvant High Dose Interleukin-2 in Patients With High Risk Stage III or IV Renal Cell Carcinoma


**EORTC-30904, MRC-RE02** Phase III Randomized Study of Radical vs Kidney Sparing Surgery for Patients With Resectable Renal Cell Cancer


**EORTC-30951** Phase III Randomized Study of Interferon Alfa With vs Without Isotretinoin in Patients With Metastatic Renal Cell Cancer


**Prostate Cancer**

**High Priority**

**VA-CSP-407, NCI-T94-0131O, PIVOT-1, CLB-9492 NCI HIGH PRIORITY CLINICAL TRIAL — Phase III Randomized Study of Prostatectomy vs Expectant Observation With Palliative Therapy for Stage I/II Prostate Cancer (PIVOT)**


**Early Detection**

**MSKCC-98014, NCI-G98-1445** Phase III Randomized Study of the Effect of a Diet Low in Fat and High in Soy, Fruits, Vegetables, Green Tea, Vitamin E, and Fiber on PSA Levels in Patients With Prostate Cancer


**PLCO-1, NCI-P93-0050** A 16-Year Randomized Screening Study for Prostate, Lung, Colorectal, and Ovarian Cancer - PLCO Trial


**Prevention**

**NCI-98-C-0099B** Phase I Randomized Study of Genistein for Prevention of Cancer in Patients With No History of Cancer or With Asymptomatic Early Prostate Cancer or Other Malignancy


**Legend for Abbreviations:**

- **CLB** = Cancer & Leukemia Group B
- **CWG** = Cytokine Working Group
- **E** = Eastern Cooperative Oncology Group
- **EORTC** = European Organization for Research on Treatment of Cancer
- **EU** = European Voluntary Protocol
- **FRE** = French Protocol
- **MRC** = UK Medical Research Council
- **MSKCC** = Memorial Sloan-Kettering Cancer Center
- **NCI** = National Cancer Institute
- **PIVOT** = Prostate Cancer Intervention vs Observation Trial
- **PLCO** = NCI Prostate, Lung, Colorectal & Ovarian Cancer Screening Trial
- **VA-CSP** = VA Cooperative Studies Program